Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

BACKGROUND: Approximately 50% of melanomas harbor activating (V600) mutations in the serine–threonine protein kinase B-RAF (BRAF). The oral BRAF inhibitor vemurafenib (PLX4032) frequently produced tumor regressions in patients with BRAF V600–mutant metastatic melanoma in a phase 1 trial and improved...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sosman, Jeffrey A., Kim, Kevin B., Schuchter, Lynn, Gonzalez, Rene, Pavlick, Anna C., Weber, Jeffrey S., McArthur, Grant A., Hutson, Thomas E., Moschos, Stergios J., Flaherty, Keith T., Hersey, Peter, Kefford, Richard, Lawrence, Donald, Puzanov, Igor, Lewis, Karl D., Amaravadi, Ravi K., Chmielowski, Bartosz, Lawrence, H. Jeffrey, Shyr, Yu, Ye, Fei, Li, Jiang, Nolop, Keith B., Lee, Richard J., Joe, Andrew K., Ribas, Antoni
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3724515/
https://ncbi.nlm.nih.gov/pubmed/22356324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1112302
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados